1992—2015年东南亚地区通过疫苗接种控制乙型肝炎的现状与进展
东南亚地区免疫技术咨询组于2016年提出到2020年5岁儿童乙型肝炎表面抗原(HBsAg)流行率≤1%的区域目标。该综述汇总1992—2015年疫苗接种数据与文献,并用数学模型估算无血清学调查国家5岁儿童HBsAg流行率及接种对疾病负担的影响。
要点
- 2015年区域估算5岁儿童HBsAg流行率为1.1%,各国间存在差异。
- 2015年区域HepB3覆盖率87%,HepB-BD覆盖率34%。
核心结论
- 尽管东南亚地区在乙型肝炎控制方面取得显著进展,仍需争取消除工作的政治承诺,并考虑促进卫生机构分娩、普及出生剂量接种、加强卫生部门间协调及使用替代疫苗递送方法等额外策略,以提高HepB-BD覆盖率,进而实现HBV控制与消除。
研究设计与样本
- 综述1992—2015年东南亚地区通过疫苗接种控制乙型肝炎的进展,汇总乙型肝炎疫苗接种数据并复习文献以确定疫苗引入前后慢性HBV感染流行率。
- 使用数学模型确定缺乏全国血清学调查数据的国家5岁儿童疫苗引入后HBsAg流行率,并估算接种对疾病负担的影响。
主要发现
- 区域三剂乙型肝炎疫苗(HepB3)覆盖率从2011年56%升至2015年87%。
- 截至2016年,11个国家中7个已引入普及性乙型肝炎疫苗出生剂量(HepB-BD);区域HepB-BD覆盖率从2011年9%升至2015年34%。
- 2015年估算5岁儿童HBsAg为1.1%,各国间存在差异;缅甸(3.8%)、东帝汶(2.7%)、印度尼西亚(1.8%)和印度(1%)HBsAg流行率最高。
- 2015年东南亚地区约发生197,640例围产期HBV感染,多数发生在印度(62%)、孟加拉国(24%)和缅甸(8%);缅甸围产期慢性HBV感染率最高,为每1000活产16例。
关键数值与推荐
- 2016年东南亚地区免疫技术咨询组认可的区域目标为到2020年5岁儿童HBsAg流行率≤1%。
- 慢性HBV感染可通过出生剂量乙型肝炎疫苗(HepB-BD)后续加2至3剂额外剂量 largely 预防。
临床怎么用
- 作者认为东南亚地区需争取消除工作的政治承诺,并考虑促进卫生机构分娩、普及出生剂量接种、建立卫生部门间强协调及使用替代疫苗递送方法等额外策略,以提高HepB-BD覆盖率并进而实现HBV控制与消除。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2016, the Immunization Technical Advisory Group of the South-East Asia Region (SEAR) endorsed a regional goal to achieve ≤1% prevalence of hepatitis B surface antigen (HBsAg) among 5-year-old children by 2020. Chronic hepatitis B virus (HBV) infection is largely preventable with a birth dose of hepatitis B vaccine (HepB-BD) followed by two to three additional doses. We reviewed the progress towards hepatitis B control through vaccination in SEAR during 1992-2015. We summarized hepatitis B vaccination data and reviewed the literature to determine the prevalence of chronic HBV infection pre- and post-vaccine introduction. We used a mathematical model to determine post-vaccine prevalence of HBsAg among 5 year olds in countries lacking national serosurvey data and estimated the impact of vaccination on disease burden. Regional coverage with three doses of hepatitis B vaccine (HepB3) increased from 56% in 2011 to 87% in 2015. By 2016, 7 of 11 countries had introduced universal HepB-BD. Regional HepB-BD coverage increased from 9% in 2011 to 34% in 2015. In 2015, estimated HBsAg among 5 year olds was 1.1% with variability among countries. Myanmar (3.8%), Timor-Leste (2.7%), Indonesia (1.8%), and India (1%) had the highest prevalence of HBsAg. During 1992-2015, vaccination prevented approximately 16 million chronic HBV infections and 2.6 million related deaths. In 2015, around 197,640 perinatal HBV infections occurred in SEAR with majority occurring in India (62%), Bangladesh (24%), and Myanmar (8%). Myanmar had the highest rate of perinatal chronic HBV infections at 16 per 1000 live births. Despite significant progress in the control of HBV, SEAR needs to secure political commitment for elimination and consider additional strategies, such as promoting health facility births, universal birth dose administration, developing strong coordination between health sectors, and using alternative vaccine delivery methods, to improve HepB-BD coverage and subsequently achieve HBV control and elimination.
引用
- Childs L, Roesel S, Tohme RA, et al. Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992-2015. Vaccine. 2017. PMID: 29174317. doi:10.1016/j.vaccine.2017.11.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。